Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 282010
IPSCIO Record ID: 368508
Licensor has determined that the key to making a useful tumor-targeting drug is the targeting mechanism that selects tumor cells while ignoring healthy ones. Cintredekin besudotox is a recombinant protein consisting of a single molecule composed of two parts a tumor-targeting molecule (interleukin-13) and a cytotoxic agent (Pseudomonas Exotoxin, or PE). IL13 receptors are found on malignant glioma cells, but not on healthy brain cells. The IL13 portion binds to receptors on the tumor like a key fits into a lock. The cancer cell latches onto and absorbs the IL13 and the attached PE, causing destruction of the cancer cell. Healthy brain cells appear to be unharmed because they do not have the IL13 receptors, and thus do not ingest the PE. IL13-PE38QQR has received orphan drug designation in Europe and the U.S., and fast track drug development program status from the U.S. Food and Drug Administration (FDA).
App. No. PCT/US00/31044 – Use of the Product in gene therapy applications to treat human cancers.
App. No. PCT/US01/25663 – Use of the Product in gene therapy applications to treat human cancers.
IL13 shall mean hIL13-PE38QQR and/or cphIL13-PE38QQR.
Product(s) shall mean any pharmaceutical product containing IL13 as the active component, in any formulation or dosage.
Licensed Technology shall mean any technology, know-how and other intellectual property (other than Trademarks) directed to IL13 and/or Products, formulations and/or methods Controlled on the Effective Date or to be Controlled during the Term and the Additional Term by Licensor or its Affiliates which are necessary or useful to research, Develop, use or Commercialize IL13 and/or the Product in the Territory in the Field of Use and shall include the Licensed Patent Rights and any Licensor Data.
Glioblastoma, also known as glioblastoma multiforme (GBM), is the most aggressive type of cancer that begins within the brain.
Field of Use shall mean, for each patent or application included in the Licensed Patent Rights listed hereto, the field of use designated below for such patent estate, and for any other Licensed Technology, the Field of Use shall mean the field of use for treating human cancer.
Licensed Fields of Use Use of the Licensed Product(s) and/or the Licensed Process(es) in gene therapy applications to treat human cancers. Specifically, transfection of cancer cells with the IL-13 Receptor-alpha-2 (IL-13Ra2) claim in order to sensitize such cells to the therapeutic effects of the IL-13 Receptor targeted immunoconjugates, hIL-13-PE38QQR or cphIL-13-PE38QQR, which were exclusively licensed to Licensee under DHHS exclusive patent license L-226-96/0.
IPSCIO Record ID: 372536
L-Nucleoside Dimer Compounds and Therapeutic Uses;
Nucleoside Analogs and Uses Against Parasitic Infection;
Novel Nucleoside Analogs and Uses in Treating Plasmodium Falciparum; and,
Novel Nucleoside Analogs and Uses in Treating Diseases.
Licensor has certain Patent Rights and Know-how relating to a family of proprietary compounds capable of selectively delivering therapeutic drugs to diseased cells.
Compounds evolving from Licensorâ€™s L-nucleoside conjugate technology take advantage of cell membrane changes that differentiate cancerous cells from healthy cells. This anomalous characteristic of cancer cell membranes presents a unique opportunity for targeting these cells with new products which are uniquely designed cytotoxic nucleosides that selectively enter cancerous cells.